Please ensure Javascript is enabled for purposes of website accessibility

Is Novavax Stock a Buy?

By Taylor Carmichael - Jun 26, 2021 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The tiny biotech has had a magnificent run from $4 a share to $200. Can the stock run higher still?

Novavax (NVAX -8.19%) has had an incredible run over the last year and a half, jumping from $4 a share in January 2020 to a recent price of $200. Is the stock still a buy? What's the long-term future for this vaccine biotech?

Corinne Cardina, bureau chief of healthcare and cannabis for the Motley Fool, and writer Taylor Carmichael discuss the future of Novavax stock. This Fool Live clip was recorded on June 18.

Corinne Cardina: Slido question for you, from Bhanu, "Is Novavax stock a buy today? What are the long-term prospects in a year or two once COVID-19 calms down?"

Taylor Carmichael: That's a very good question. I do think it's a buy. It's had an incredible run. I mean, the stock was trading in January last year, was trading at $4 and now it's a little under $200. It's had an amazing run, it's a $14 billion company. They are going to be one of the major COVID-19 vaccine providers in the world. ModernaPfizer, Novavax, maybe Johnson & Johnson, maybe AstraZeneca, but they're definitely, Novavax is going to be major and they're going to make a lot money, they are going to make billions of dollars from this vaccine. What we don't know is how much we're going to have to continue to vaccinate over COVID-19, and that's a question of mutation. If it mutates enough and it mutates every year, we're going to have to revaccinate and revaccinate, like we do with the flu. The flu mutates all the time. Novavax is a flu specialist. They've also got a flu vaccine. They got, in my opinion, the best flu vaccine in the world. It hasn't been approved yet, but they've got wonderful phase 3 data and they went head to head in competition with Sanofi's vaccine. They are the market leader in flu vaccines and Novavax just dusted them in the animal data phase 1, phase 2, and phase 3. Novavax ultimately is going to do a combination vaccine, combination flu, COVID-19.

Cardina: They hope to. [laughs]

Carmichael: Right. They're going to do phase 1 human trial. They had positive animal data, they're going to do phase 1 trials later this year. Flu is about a $5 billion dollar market. COVID is a massive, I mean, just unbelievably large market. What we don't know and nobody knows really is, how big is that market going to remain? Is this going to be something that stays with us over the next decade, are we going to constantly vaccinate from COVID-19 or we are all going to build up an immunity and it just disappears? If it disappears, then this massive revenue that Novax it's going to be more like a lump, the revenues are going to come down to earth. I think of Novavax as one of the premier vaccine companies, and the market has radically changed the valuation of vaccine companies. And we've seen with COVID-19 how important vaccination can be. So there are risks. What was at risk of Novavax at the beginning, $4 a share, it was execution risks. But now the risk is a valuation risk. Are there cheaper stocks out there? Absolutely. It's one of my family's largest holdings, Novavax. I'm a big believer in the company, I love their story. I think it's going to be a great stock, I'm definitely a holder, and it's expensive at $200 a share or $190, wherever it is now. But I think over the next year, I'm certain, as certain as I can be, that they're going to get that EUA from the FDA, and then they're going to have these magnificent numbers. I think the market is discounting that possibility, so I think in the near term, I think it's going to be pretty fun ride for investors. Over the long term, it's unknowable because we don't know how COVID's going to shake out.

Corinne Cardina owns shares of Moderna Inc. Taylor Carmichael owns shares of Novavax. The Motley Fool recommends Johnson & Johnson and Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$39.37 (-8.19%) $-3.51
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.27 (-1.18%) $0.59
Johnson & Johnson Stock Quote
Johnson & Johnson
$167.58 (0.01%) $0.01
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.42 (-0.48%) $0.32
Sanofi Stock Quote
$42.18 (-5.87%) $-2.63
Moderna, Inc. Stock Quote
Moderna, Inc.
$158.00 (-5.93%) $-9.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.